Close menu




November 27th, 2020 | 10:24 CET

Varta, Royal Helium, NEL ASA: After the hype is before the hype

  • Investments
Photo credits: pixabay.com

The world is facing a whole series of revolutions. Digitalization is changing business models and the way we work and communicate. New energy sources are revolutionizing mobility. Between April and October, Varta's stock posted an impressive performance and generated a return of more than 150%. Recently, however, the share price has come down a little again. Reason enough to put the Company through its paces a little. Varta manufactures micro-batteries, such as those used in hearing aids or other household appliances. By the end of next year, Varta intends to expand its capacities in this area. The Company is also taking a step forward in terms of quality and plans to increase energy density further, and this is how the Company intends to stand out from the cheap competition.

time to read: 3 minutes | Author: Nico Popp
ISIN: NO0010081235 , CA78029U2056 , DE000A0TGJ55

Table of contents:


    Varta: Is history repeating itself?

    In recent months, the share has been celebrated by investors, particularly for its fantasy about entering the field of electromobility. Thanks to public funding of EUR 300 million, Varta could gain access to a lucrative market. Coupled with the positive forecasts in the core business with batteries for hearing aids or headphones, this price fantasy has boosted the share.

    However, the management could no longer convince analysts and the first observers expressed doubts about the equity story. The competition from Asia should also be mentioned in this context: It would not be the first time that German companies in a technology of the future are ultimately at a disadvantage compared to China, despite generous subsidies - the situation was similar years ago with photovoltaic stocks. The Varta share is, rightly, currently undergoing a consolidation. The music is out for now.

    Royal Helium: Revaluation still in December?

    The share of Royal Helium went into reverse in the past months. The Canadian second-tier stock is looking for the noble gas helium in the south of the Canadian province of Saskatchewan. The gas has unique properties and can be used in many areas: the largest area of application is in medical technology, where it is found in MRI equipment. The noble gas can also be used in the manufacture of computer chips and in the quality testing of batteries. Helium can thus do much more than making balloons rise. The analysts at Cormark Securities also see it that way and expect a shortage of helium in the coming years.

    Royal Helium wants to take advantage of this and further advance its Canadian helium project. With 400,000 hectares of land and surrounded by crucial infrastructure, the property is considered promising. Royal Helium is currently conducting a technical investigation to evaluate the economics of a gas processing plant. The Company points out that the property may also have the potential to market by-products in the form of other gases. The Company plans to present the first results of the study in December. Royal Helium's shares may have attractive prospects due to the many uses of helium in the medical, semiconductor and battery sectors.

    NEL ASA: Hydrogen hope at a crossroads

    NEL's share certificates are also full of promise. The Norwegian hydrogen specialist takes care of the production of hydrogen, its storage and distribution. Thus, NEL covers all aspects of hydrogen. If you imagine a future full of hydrogen cars, you can hardly avoid solutions from the Norwegians. Hydrogen as an energy carrier is regarded as a clean alternative to lithium-ion batteries, as these are dependent on numerous critical metals, the promotion of which causes environmental damage.

    Despite the rosy outlook and the catchy investment story, the NEL share has recently hit its head several times in the range of just over two euros. This zone of resistance has proven to be stubborn. According to the technical chart, the stock is now in a decision zone: If a sustained breakout above this resistance zone is achieved, further price momentum may emerge, and if the breakout is not successful, price losses are possible. Since NEL is already ambitiously valued, a correction cannot be ruled out.

    The most significant opportunities are lurking among latecomers

    Varta is a latecomer into the field of e-mobility but has already made significant gains. NEL, on the other hand, is a pioneer and well-positioned around hydrogen. The current hydrogen hype could lead to the market allowing even higher valuations. Nevertheless, investors should be aware of the high fall. Even if intact trends offer a good investment environment, it is also worth taking a look at the second tier. Helium-related stocks are also benefiting from a whole range of megatrends and are currently in low demand, allowing speculative-oriented investors to enter the market at favourable prices.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read